Estimado(a) Dr.(a) le invitamos a ver el siguiente webinar: “Importancia Del Manejo Multidisciplinario En Obesidad”.
Por el Dr. Mario Ivan Urbina Sánchez. Especialista e Medicina Interna y Obesidad. Cédula Médico General 3831834. Cédula de Especialidad 5643466.
Referencias:
1 AMA. American Medical Association, NAFLD, non-alcoholic fatty liver disease
2 American Medical Association Resolution: 420 (A-13). Available at: https//www.npr.org/documents/2013/jun/ama-resolution-obesity.pdf.
3 IL-6, interleukin 6; FGF21, fibroblast growth factor 21; MCP1, monocyte chemoattractant 1; TNF(alfa), tumour necrosis factor (alfa); PAI-1, plasminogen activator inhibitor 1; TGFB, transforming growth factor B; miRNA, micro RNAs, Adapted from Lou and Liu, Journal of Endocrinology December 2016; Ji and Guo, Nature Reviews in Endocrinology, Dec 2019
4 Pasarica, Magdalena, et al. “Reduced Adipose Tissue Oxygenation in Humsn Obesity Evidence for Rarefaction, Macrophage Chemotaxis, and Inflamation Without an Angiogenic Response.” Naitional Center for Biotechnology Information (NCBI), PubMed, 2009, www.ncbi.nlm.nih.gov/pmc/articles/PMC2646071/pdf/718.pdf.
5 Delgado-Aros et al. Gastroenterology. 2004;126:432-40
6 AMPK, adenosine monophosphate-activated protein kinase; FIAF, fasting-induced adipocyte factor Parekh et al. Clin TransI Gastroenterol 2015 18;6:e91
7 A-fib, atrial fibrallation; CAD, coronary artery disease; ED, erectible dysfunction; EOM, Eosinophilic otitis media; GDM, gestational diabetes mellitus; GORD, gastroesophageal reflux disease; HCC, hepatocellular carcinoma; HTN, hypertension; MM, multiple myeloma; NAFLD, non-alcoholic fatty liver disease; OA, osteoarthritis; VTE, venous thromboembolism Yuen et al. Obesity Week 2016. Oct 31-Nov 4 2016. New Orleans: T-P-3166
8 Badman, Flier. Science 2005;307:1909-14;2. US Department of Health and Human Services, 1998. NIH Publication No. 98-4083
9 Foresight: Tackling Obesities: Future Choices – Project Report https://assets.publishing.service.gov.uk/government/uploads/attachment_data/file/295153/07-1177-obesity.system-atlas.pdf
10 Rethink Obesity https://www.rethinkobesity.com/more-resources/educational-downloads.html
11 Charon R. JAMA. 2001;286:1897-1902;Laine C et al. JAMA. 1996;275:152-156;
12 Norman G. N Engl J Med. 2006;355L2251-2252
13 Maldonado A et al. Patient Educ Couns. 2010;79:287-290
14 Kushner RF. American Medical Association, 2003. Kushner RF et al. American Diabetic Assosiation, 2009. Kushner RF et al. JAMA. 2014:312(9):943-952
15 Schwartz et al. Obes Rev 2010;11:531-47
16 Sumithran et al. N Engl J Med 2011;365: 1597-604
17 Sharma, Kusher Int J Obes (Lond) 2009; 33:289-95
18 EMA Medicines http://www.ema.europa.eu/
Material desarrollado con fines de educación médica continua.
Material exclusivo para profesionales de la salud.
La información aquí presentada es opinión del ponente.
Código interno de aprobación: MX21SX00197
